What is vaginal DHEA?

Vaginal DHEA is a prescription suppository (brand name Intrarosa, generic name prasterone) containing 6.5 mg of dehydroepiandrosterone, inserted nightly into the vagina. It is FDA-approved for moderate-to-severe dyspareunia due to menopausal vulvovaginal atrophy.

Is vaginal DHEA the same as estradiol cream?

No. Both are local prescription options for menopausal vaginal symptoms, but they work through different mechanisms. Vaginal estradiol delivers estrogen directly. Vaginal DHEA delivers a precursor that the local tissue converts into estrogen and androgen as needed. The clinical effects overlap significantly, but the regulatory and safety profiles differ.

How long does it take vaginal DHEA to work?

Most women report meaningful improvement in dryness, irritation, and pain during intercourse within 6 to 12 weeks of nightly use. Clinical trials show measurable improvements in vaginal epithelial thickness and pH within 8 weeks.

Does vaginal DHEA raise systemic estrogen levels?

Minimally. In FDA registration trials, women using nightly Prasterone showed serum estradiol concentrations that remained within the normal postmenopausal range. Local conversion in vaginal tissue does not appear to produce significant systemic exposure.

Can I use vaginal DHEA if I have a breast cancer history?

This is a decision that must be made with your oncology team. Vaginal DHEA does increase local intracellular estrogen and androgen levels. While systemic exposure is low, women with a history of estrogen-receptor-positive breast cancer are a special population and should not initiate Prasterone without explicit oncologist sign-off.

What are the side effects of vaginal DHEA?

The most commonly reported side effects are vaginal discharge (typically due to the oil-based suppository melting) and minor application-site irritation. Systemic side effects are rare given limited absorption.

Is there an over-the-counter vaginal DHEA?

No. Prasterone is prescription-only in the United States. Some OTC topical creams marketed as “DHEA cream” are sold for facial or body use; these are not the same product, are not approved for intravaginal use, and have wide variability in actual DHEA content.

Does insurance cover Prasterone?

Coverage varies widely. Some commercial plans cover Intrarosa with prior authorization, others do not cover it at all. Out-of-pocket cost is typically $180–$220/month, though manufacturer copay cards and compounded prasterone through specialty pharmacies can lower the price.

Vaginal DHEA (Prasterone): How Intrarosa Treats Menopausal Symptoms

Roughly half of postmenopausal women in the United States experience some form of vulvovaginal atrophy — dryness, burning, painful intercourse, urinary irritation. The condition has a name (genitourinary syndrome of menopause, or GSM), a known cause (declining local estrogen), and several effective treatments. The treatment that almost no general practitioner brings up first is vaginal DHEA.

What Vaginal DHEA Actually Is

Vaginal DHEA, sold under the brand name Intrarosa and known generically as prasterone, is a 6.5 mg dehydroepiandrosterone suppository inserted into the vagina once nightly. It was approved by the FDA in November 2016 for one specific indication: moderate-to-severe dyspareunia (painful sexual intercourse) due to menopausal vulvovaginal atrophy. Some clinicians prescribe it off-label for related symptoms — vaginal dryness without pain, recurrent urinary tract infections of postmenopausal origin — but the registration indication is narrow.

Prasterone is, chemically, the same DHEA molecule that you can buy in capsule form at any pharmacy. What makes it different is the delivery route, the dose, the regulatory status, and the manufacturing oversight. A retail oral DHEA capsule contains 5–100 mg of variable-purity material; a Prasterone insert contains exactly 6.5 mg of pharmaceutical-grade prasterone in a vegetable-fat suppository base that melts at body temperature.

How Vaginal DHEA Works — Locally, Not Systemically

This is the part of the mechanism that most patient-facing material gets wrong. Prasterone is not pushing estrogen into your bloodstream. It is placing a hormone precursor directly against the vaginal epithelium, where local enzymes (3β-HSD, 17β-HSD, aromatase) convert it into estradiol and testosterone within the tissue itself. Those locally produced hormones bind locally to receptors in vulvar and vaginal cells, restoring epithelial thickness and lubrication.

The clinical implication of this “intracrine” mechanism is that systemic exposure stays remarkably low. In Phase III trials, postmenopausal women on nightly Prasterone for 12 weeks showed serum estradiol and testosterone levels that remained inside the normal postmenopausal range. That is a meaningfully different safety profile from systemic oral estrogen — and is the reason Prasterone is sometimes considered for women who want symptomatic relief without raising whole-body estrogen.

Vaginal DHEA vs Estradiol Cream

Both prasterone and local estradiol (creams, tablets, rings) effectively treat vaginal atrophy. The differences come down to mechanism, formulation, dosing rhythm, and physician preference. The honest comparison:

Mechanism. Estradiol delivers estrogen directly. Prasterone delivers DHEA, which the tissue converts to estradiol and small amounts of testosterone locally. Both restore epithelial thickness; the prasterone path additionally raises local testosterone, which may matter for women with androgen-deficiency-linked symptoms (sensitivity, libido at the tissue level).
Dosing rhythm. Vaginal estradiol cream is typically used nightly for two weeks, then twice weekly. Prasterone is dosed nightly indefinitely. Some women prefer the simpler “same routine every night” of prasterone; others prefer the twice-weekly cadence of maintenance estradiol.
Form factor. Estradiol comes as a cream (applicator-dispensed), a vaginal tablet, or a slow-release ring. Prasterone is only available as a suppository.
Systemic exposure. Both are low; trial data on prasterone keep women in postmenopausal range, and modern low-dose vaginal estradiol generally does the same.
Discharge. Prasterone produces more discharge than estradiol cream because the entire 6.5 mg suppository melts and is partially expelled overnight. Women who find this bothersome sometimes prefer the smaller-volume estradiol tablet.
Insurance coverage. Generic vaginal estradiol is broadly covered. Prasterone (still branded; generic became available in some markets in 2024) is often more expensive without prior authorization.

Who Should Consider Vaginal DHEA?

The clearest candidates are postmenopausal women with moderate-to-severe dyspareunia who have not responded adequately to over-the-counter lubricants and moisturizers, or who have failed vaginal estradiol. Prasterone may also be the better first option for:

Women who want a single, simple nightly routine without titration.
Women for whom local estrogen produces irritation or who prefer not to use estrogen-named products.
Women whose symptoms include both dryness and reduced tissue sensitivity / arousal — the androgen-precursor element may be relevant here.
Women with concomitant urinary symptoms; some clinical evidence suggests Prasterone may reduce recurrent UTI episodes in this population.

Anatomical editorial illustration of female pelvic anatomy — The vaginal epithelium contains the enzymatic machinery to convert DHEA into local estradiol and testosterone — the principle behind Prasterone’s intracrine action.

How to Use Vaginal DHEA

The standard regimen is one 6.5 mg insert intravaginally at bedtime, every night, indefinitely. There is no “loading dose” followed by a maintenance phase — the dose is the same on night one as on night 365. The product comes with single-use plastic applicators; insertion technique is similar to a tampon. Women are advised to lie down for application and to not insert during menstruation (a non-issue for the typical postmenopausal user).

Re-evaluation at 12 weeks is standard. If symptoms have meaningfully improved, treatment continues. If they have not — which is uncommon but does occur — a switch to or addition of local estradiol is the typical next step.

The “DHEA Cream” Confusion

When women search “DHEA cream,” they are almost never asking for the same thing. The query covers at least three distinct products:

Vaginal Prasterone (Intrarosa). Prescription, 6.5 mg suppository. This is the FDA-approved DHEA product.
Over-the-counter topical DHEA creams. Sold online and in some pharmacies, marketed for skin elasticity, anti-aging, and (unofficially) hormonal balance. These have wide variability in actual DHEA content and minimal evidence for the claimed indications. They are not approved for intravaginal use, even though some are placed on or near the vulva by users.
Compounded transdermal DHEA cream. Pharmacy-compounded on a clinician’s prescription for systemic absorption, typically in doses of 2–10 mg/day. Used off-label primarily for women with documented adrenal insufficiency.

These three are not interchangeable. The first is a regulated drug. The second is a supplement-aisle product with no quality oversight beyond DSHEA. The third is a compounded preparation that operates somewhere between the two regulatory worlds. If your clinician “recommends DHEA cream,” the first follow-up question should be which one.

Side Effects to Expect

The Prasterone trial data and post-marketing surveillance both suggest a favorable side-effect profile. The most commonly reported issues are local:

Vaginal discharge — the suppository base melts at body temperature, so some discharge in the morning is expected, not a complication.
Minor application-site irritation or itching in a small percentage of users, usually self-limiting.
Pap smear changes were not observed at clinically meaningful rates in the registration trials.

Serious systemic side effects (clot risk, breast tenderness, mood changes) have not been signaled in the available data, consistent with the low systemic exposure profile. The package insert lists endometrial cancer risk language as a class effect carried over from estrogen products, although direct evidence of endometrial stimulation from vaginal prasterone is essentially absent.

Getting Prescribed Vaginal DHEA: The Telehealth Path

Until recently, the realistic path to a Prasterone prescription required either an OB/GYN who actively kept up with menopause literature (a minority of practitioners, per published surveys of US obstetrician-gynecologists) or a NAMS-certified menopause practitioner (still under 3,000 nationwide). Most women hit a wall in primary care: their symptoms were normalized, lubricant was recommended, and the conversation ended.

That bottleneck is what telehealth menopause practices have specifically built around. The process now looks like:

A short structured intake focused on genitourinary symptoms, menopausal stage, and contraindications (breast cancer history, undiagnosed bleeding, active clotting disorders).
A consult with a licensed clinician — typically a nurse practitioner with menopause specialty training, or an MD — who reviews the intake, confirms or rules out the GSM diagnosis, and discusses options.
If Prasterone is appropriate, a prescription is sent electronically to a partner specialty pharmacy that delivers a discreet 30-day supply.
A 12-week re-evaluation video appointment, with a structured symptom score comparison.

The economic and practical accessibility of this path is what has driven the largest year-over-year increase in prasterone prescriptions in recent CMS data. The clinical care itself is not novel — what is novel is that women can actually get to a prescriber who knows what they are doing without waiting 11 weeks for an OB/GYN consult.

The Honest Bottom Line

Vaginal DHEA is one of the better-supported, more elegant prescription options in the menopause toolkit. The mechanism is clean (local intracrine conversion), the safety profile is favorable (minimal systemic exposure), and the symptomatic improvement in dyspareunia and dryness is clinically meaningful in well-conducted trials. It is also the only DHEA product on the US market that has gone through the FDA drug approval process — which is meaningful in a category otherwise dominated by unverified retail supplements.

It is not magic. It is one of several appropriate options for GSM. Many women do equally well on vaginal estradiol. The clinical decision should be made with a provider who can read your full picture — but the decision should at least be offered, and for too many women in this country, it currently isn’t.